- June 6, 2018
- Posted by: PharmaScroll
- Category:
Presentations include clinically meaningful, comprehensive and durable benefits observed in two pivotal Phase 3 clinical trials of rimegepant for the acute treatment of migraine
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced that expanded data from two randomized, pivotal Phase 3 clinical trials of rimegepant, along with other important preclinical and clinical results, will be presented at the American Headache Society (AHS) 60th Annual Scientific Meeting in San Francisco, CA, June 28-July 1, 2018.
Biohaven is presenting further results from its two pivotal Phase 3 clinical trials with rimegepant in the acute treatment of migraine. Researchers will present data on the durability and consistency of clinical effect seen with a single oral dose across multiple outcome measures from both trials. Biohaven will also present results from a preclinical study in which its CGRP receptor antagonists were not observed to have vasoconstrictive properties in human coronary or cerebral arteries. Expanded data from a Phase 1 trial evaluating the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant also will be discussed.
Vlad Coric, M.D., CEO of Biohaven commented, “We are grateful to the AHS for accepting four late-breaking presentations regarding rimegepant. Biohaven is pleased to be able to present the full breadth of our Phase 3 trials that demonstrate the clinical benefit of rimegepant on multiple outcome measures important to migraine patients, including sustained pain freedom and pain relief, and improvement on measures of functional disability. We are also excited to present in vitro human artery data supporting the potentially favorable cardiovascular profile of rimegepant. The Biohaven team looks forward to sharing our clinical and preclinical results with the patients and medical community at AHS.”
The schedule of Biohaven presentations at AHS includes:
- Late-breaking oral presentation IOR-02LB
Title: Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-Blind, Randomized, Placebo-Controlled Trial, Study 302
Date and Time: Saturday, June 30, 10:00-10:10 a.m.
Presenter: Richard B. Lipton, MD, Albert Einstein College Of Medicine
- Late-breaking poster presentation PS123LB
Title: Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Double-Blind, Randomized, Placebo-Controlled Trial, Study 301
Date and Time: Saturday, June 30 (all day with presenter Q&A 1:00-2:15 p.m.)
Presenter: Richard B. Lipton, MD, Albert Einstein College Of Medicine
- Late-breaking poster presentation PF116LB
Title: A Phase 1 Study to Evaluate the Bioequivalence of Oral Tablet and Orally Dissolving Tablet Formulations of Rimegepant in Healthy Adult Subjects Under Fasting Conditions
Date and Time: Friday, June 29 (all day with presenter Q&A 1:15-2:15 p.m.)
Presenter: Robert Croop, MD, Biohaven
- Late-breaking oral presentation LBOR-08
Title: Rimegepant and BHV-3500, Small Molecule CGRP Receptor Antagonists, Exhibit No Active Vasoconstrictive Properties in Ex Vivo Human Coronary or Cerebral Arteries
Date and Time: Saturday, June 30, 3:05 PM – 3:15 p.m.
Presenter: Charles M. Conway, PhD, Biohaven
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Migraine, visit https://pharmascroll.com/news-category/migraine/
News Source: Biohaven website
Image Source: https://pharmaphorum.com/news/biotech-ipo-market-heats-biohaven-makes-debut/